Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Non-Current Assets (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Other Non-Current Assets for 13 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 94.38% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 94.38% year-over-year, with the annual reading at $4.1 million for FY2025, 94.38% down from the prior year.
  • Other Non-Current Assets hit $4.1 million in Q4 2025 for Coherus Oncology, down from $4.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $72.2 million in Q4 2024 to a low of $4.1 million in Q4 2025.
  • Historically, Other Non-Current Assets has averaged $11.4 million across 5 years, with a median of $8.9 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: soared 2867.96% in 2021 and later crashed 94.38% in 2025.
  • Year by year, Other Non-Current Assets stood at $10.0 million in 2021, then decreased by 13.54% to $8.7 million in 2022, then increased by 11.74% to $9.7 million in 2023, then soared by 645.2% to $72.2 million in 2024, then plummeted by 94.38% to $4.1 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CHRS at $4.1 million in Q4 2025, $4.4 million in Q3 2025, and $5.0 million in Q2 2025.